OneSource
- Company typePublic
- Founded2024
- HeadquartersBangalore, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
OneSource firmographics
Firmographics- Name
- OneSource
- Legal name
- OneSource Specialty Pharma Limited
- Website
- https://onesourcecdmo.com
- Company type
- Public
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
OneSource industry classification
Industry- Product category
- Pharmaceutical CDMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Small-Molecule API & Intermediates CDMO (HLAGABAA)
Keywords
Where OneSource is headquartered
LocationHeadquarters
- HQ city
- Bangalore
- HQ country
- India
- HQ region
- Asia
Offices5 records
Markets served
OneSource business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Development and Manufacturing Services (CDMO): End-to-end CDMO services spanning early-stage development, clinical supply, and commercial manufacturing. Revenue generated through development fees, manufacturing service fees, and long-term supply agreements. The company signs Master Service Agreements (MSAs) with customers; signed 9 new MSAs in Q2FY26. Revenue model is transitioning toward IP-led base business sales and Take-and-Pay contracts linked to commercial supply of products like semaglutide.
- IP-Led Base Business: Revenue from intellectual property-led base business including commercialized products manufactured for partners. Includes 19 commercialized drug products in the United States and multiple approved ANDAs across sterile injectables, biologics, and drug-device combinations.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
OneSource product offering
Product offeringCore offering
OneSource is a specialty pharma Contract Development and Manufacturing Organization (CDMO) offering end-to-end services from early-stage development through commercial manufacturing across four core platforms: drug-device combinations, complex sterile injectables, biologics, and soft gelatin capsules. The company manufactures pharmaceutical products under Master Service Agreements and supply contracts for global pharmaceutical and biotech clients, operating from five US FDA-approved facilities in Bengaluru, India. Strategic offerings include peptide GLP-1 manufacturing (semaglutide), proprietary HILOPRO® high-concentration formulation platform, and SEDDS/SMEDDS/SNEDDS lipid softgel technology.
Product overview
OneSource Specialty Pharma is a multimodal specialty pharma Contract Development and Manufacturing Organization (CDMO) offering end-to-end CDMO services across four core technology platforms: drug-device combinations (prefilled syringes, pen injectors, autoinjectors), complex injectables (sterile liquids, lyophilized vials, dry powder), biologics (microbial/mammalian cell line, cell & gene therapy, RNA), and soft gelatin capsules (2.4 billion capsules/year capacity). The company operates five USFDA-approved facilities in Bengaluru, India, providing integrated services from early-stage development through commercial manufacturing. Strategic proprietary platforms include the HILOPRO® high-concentration subcutaneous formulation platform, self-emulsifying softgel technology (SEDDS/SMEDDS/SNEDDS), and a GLP-1 peptide development platform. The company was demerged from Strides Pharma in 2024 and listed separately in January 2025.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug-Device Combinations Manufacturing End-to-end development and manufacturing of specialized drug-device combination products for pharmaceutical and biotech clients, including prefilled syringes, dial-and-push variable and fixed-dose pen injectors, pull-push fixed-dose pens, and autoinjectors. Supported by 20+ automatic and semi-automatic flexible assembly stations across multiple device formats.
- Complex Injectables Manufacturing Development and manufacturing of complex injectable drug products in multiple dosage forms including sterile liquids, lyophilized vials, prefilled syringes, and dry powder injections for global pharmaceutical clients. Backed by 35 approved ANDAs and 19 commercialized drug products in the United States.
- Biologics Manufacturing Integrated biologics development and manufacturing services covering microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products, with 550,000 ft² of dedicated process development and drug substance manufacturing space at the Bengaluru campus.
- Soft Gelatin Capsules (Softgels) Development and manufacturing of soft gelatin capsule technologies with 2.4 billion capsules per year capacity, including traditional softgels, enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories across multiple shapes and sizes.
- Generic Semaglutide CDMO Manufacturing End-to-end contract manufacturing of generic semaglutide injection (generic Ozempic GLP-1 therapy) for global pharmaceutical partners including Dr. Reddy's, Apotex/Orbicular, and Hikma Pharmaceuticals across Canada, US, Saudi Arabia, and MENA markets.
Quantifiable outcome
- 232.4% CAGR in consolidated revenue between FY23 and FY26 — fastest among Indian pharma companies analyzed
- +4 more outcomes
Companies that use OneSource
Customer profileNamed customers5 records
Segments1 record
Ideal customer profiles1 record
OneSource technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
OneSource partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered minor, core and strategic.
- Brooks SteriscienceminorOneSource's board decided not to proceed with the proposed transaction with Brooks Steriscience, stating it was not in the best interest of stakeholders. Brooks Steriscience echoed a similar stance, confirming termination of the proposed transaction. The deal was part of a Composite Scheme of Arrangement that also involved Steriscience Pte Limited and Strides Pharma Services Private Limited. No reasons were provided for the decision.
- Orbicular Pharmaceutical TechnologiescoreOrbicular Pharmaceutical Technologies led product development and technical program for generic Ozempic (semaglutide injection), with OneSource providing end-to-end manufacturing from its US FDA-approved Bengaluru facility. The partnership secured tentative US FDA approval (April 2026) and Health Canada approval (May 2026), making it one of the first generic entrants in both markets. Orbicular used its Canadian front-end partner for the Apotex approval and a US-based ANDA holder for the US market.
- Dr. Reddy's LaboratoriescoreOneSource serves as CDMO (Contract Development and Manufacturing Organization) partner for Dr. Reddy's generic semaglutide injection (generic Ozempic). OneSource manufactures the finished product at its US FDA-approved Bengaluru facility while Dr. Reddy's produces the active pharmaceutical ingredient (API) in-house. Health Canada granted approval in April 2026, making it the first generic semaglutide approval in Canada (a G7 market). The Canadian market is estimated at $1.5-1.8 billion. A second approval followed for Apotex, also manufactured by OneSource.
- Hikma PharmaceuticalscoreExclusive partnership for commercializing generic Ozempic (semaglutide) in Saudi Arabia and the broader Middle East and North Africa (MENA) region. OneSource manufactures and supplies the drug from its Bengaluru facility while Hikma Pharmaceuticals (largest pharmaceutical company in MENA by sales) handles commercialization through its established commercial network and institutional relationships. SFDA approval secured in February 2026.
- Xbrane BiopharmastrategicOneSource and Xbrane Biopharma announced a biosimilars manufacturing partnership for global markets in June 2025. OneSource will provide manufacturing capabilities for Xbrane's biosimilar programs targeting global commercialization.
- Bhami Research LabstrategicOneSource accesses the patented HILOPRO high-concentration formulation platform through strategic partnership with Bhami Research Lab. The platform is validated across six commercial molecules and enables subcutaneous delivery of high-dose biologics by solving viscosity and concentration challenges.
Scale indicators15 records
Recent moves9 records
Expansion highlights5 records
OneSource competitors and assessment
Company assessmentDirect peers
- Syngene International: Indian-listed CRO/CDMO with biologics manufacturing and integrated discovery-to-commercial services for global pharma. Directly comparable in business model and customer base (innovator biopharma), though Syngene leans more discovery/research-heavy.
- Suven Pharmaceuticals: Indian CDMO with capabilities in intermediates, APIs, and formulations including complex injectables. Comparable as a contract-focused Indian pharma services business serving global innovators and generics players.
- Jubilant Pharmova: Indian pharma company with CDMO operations in sterile injectables, APIs, and radiopharmaceuticals. Comparable in modality mix (sterile injectables, complex generics) and in serving regulated markets, with FDA-approved facilities.
- Piramal Pharma Solutions: Indian-headquartered CDMO offering sterile injectables, complex APIs, and drug-device combination manufacturing for global pharma. Most direct Indian peer for OneSource's sterile injectables and complex generics work, with overlapping customers and similar regulatory profile.
- Divis Laboratories: Indian API and intermediates manufacturer with growing formulation and CDMO exposure. Comparable in regulated-market supply and scale, with similar FDA-inspected infrastructure and global pharma customer base.
Broad incumbents
- Samsung Biologics: South Korean biologics CDMO with very large single-site capacity. A direct competitor for biologics manufacturing and subcutaneous biologic programs where OneSource's HILOPRO platform plays.
- WuXi Biologics: Global biologics CDMO with end-to-end capabilities across mAbs, bispecifics, and ADCs. Comparable in biologics DS/DP integration, but at materially larger scale and with a broader innovator-biopharma customer base.
- Lonza Group: Global leader in biologics and small-molecule CDMO with end-to-end drug substance and drug product services. OneSource competes for the same complex injectables and biologics programs, but Lonza is a far larger incumbent with deeper innovator-biopharma relationships.
- Catalent (Novo Holdings): Global CDMO with leading positions in softgel, drug-device combinations, and biologics fill-finish. A direct competitor in softgels and drug-device combinations, now owned by Novo Holdings (relevant given OneSource's semaglutide exposure).
Regional players
- Aurobindo Pharma: Indian-headquartered generics manufacturer with significant injectables, biosimilars, and API operations. Comparable in sterile injectables and complex generics manufacturing, with a similar India-based, FDA-inspected footprint; primarily serves its own generic brands plus third-party CDMO.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
OneSource social profiles
Digital presenceOneSource compliance and trust
Trust signalCompliance8 records
OneSource financial estimates
Financial estimateRevenue estimate
Valuation estimate
OneSource leadership team
Management profileNumber of profiles
Profiles13 records
OneSource subsidiaries and ownership
Company hierarchySubsidiaries7 records
OneSource funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OneSource M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OneSource
What does OneSource do?
OneSource is a specialty pharma Contract Development and Manufacturing Organization (CDMO) offering end-to-end services from early-stage development through commercial manufacturing across four core platforms: drug-device combinations, complex sterile injectables, biologics, and soft gelatin capsules. The company manufactures pharmaceutical products under Master Service Agreements and supply contracts for global pharmaceutical and biotech clients, operating from five US FDA-approved facilities in Bengaluru, India. Strategic offerings include peptide GLP-1 manufacturing (semaglutide), proprietary HILOPRO® high-concentration formulation platform, and SEDDS/SMEDDS/SNEDDS lipid softgel technology.
Is OneSource a public or private company?
OneSource is a public company. It is classified as public and is currently operating.
When was OneSource founded?
OneSource was founded in 2024. It employs 1,001 to 5,000 people.
Where is OneSource based?
OneSource is headquartered in Bangalore, India, in the Asia region.
How does OneSource make money?
Two revenue lines are on record. Contract Development and Manufacturing Services (CDMO) is the primary driver. The others are IP-Led Base Business.
Who are OneSource's main competitors?
Direct peers on record are Syngene International, Suven Pharmaceuticals, Jubilant Pharmova, Piramal Pharma Solutions and Divis Laboratories. Broad incumbents are Samsung Biologics, WuXi Biologics, Lonza Group and Catalent (Novo Holdings). Aurobindo Pharma is listed as a regional player.
Does OneSource have an API?
No public API is recorded for OneSource.
What industry is OneSource in?
OneSource's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.